PDGFRB and glioblastoma: For instance, in an open-label trial of imatinib mesylate with patients with unresectable, recurrent GBM expressing PDGFR (NCT00171938, 2004), immunohistochemical documentation of expression of PDGFR was required for inclusion [97].